205 related articles for article (PubMed ID: 15086403)
1. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
Castelletti D; Fracasso G; Righetti S; Tridente G; Schnell R; Engert A; Colombatti M
Clin Exp Immunol; 2004 May; 136(2):365-72. PubMed ID: 15086403
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.
Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW
Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
[TBL] [Abstract][Full Text] [Related]
4. Peptide analogues of a T-cell epitope of ricin toxin A-chain prevent agonist-mediated human T-cell response.
Castelletti D; Colombatti M
Int Immunol; 2005 Apr; 17(4):365-72. PubMed ID: 15724064
[TBL] [Abstract][Full Text] [Related]
5. Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.
Tommasi M; Castelletti D; Pasti M; Fracasso G; Lorenzetti I; Sartoris S; Pera C; Ferrara GB; Tridente G; Colombatti M
Clin Exp Immunol; 2001 Sep; 125(3):391-400. PubMed ID: 11531946
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.
Schnell R; Borchmann P; Staak JO; Schindler J; Ghetie V; Vitetta ES; Engert A
Ann Oncol; 2003 May; 14(5):729-36. PubMed ID: 12702527
[TBL] [Abstract][Full Text] [Related]
9. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
Kornfeld SB; Leonard JE; Mullen MD; Taetle R
Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
[TBL] [Abstract][Full Text] [Related]
10. A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin.
Neal LM; O'Hara J; Brey RN; Mantis NJ
Infect Immun; 2010 Jan; 78(1):552-61. PubMed ID: 19858297
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.
Schnell R; Vitetta E; Schindler J; Borchmann P; Barth S; Ghetie V; Hell K; Drillich S; Diehl V; Engert A
Leukemia; 2000 Jan; 14(1):129-35. PubMed ID: 10637488
[TBL] [Abstract][Full Text] [Related]
12. Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.
Byers VS; Austin EB; Clegg JA; Denton G; Gunn B; Hooi D; Hudecz F; Price MR; Baldwin RW
J Clin Immunol; 1993 Nov; 13(6):406-14. PubMed ID: 7507127
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
14. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
[TBL] [Abstract][Full Text] [Related]
15. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
[TBL] [Abstract][Full Text] [Related]
16. Localization of non-linear neutralizing B cell epitopes on ricin toxin's enzymatic subunit (RTA).
O'Hara JM; Kasten-Jolly JC; Reynolds CE; Mantis NJ
Immunol Lett; 2014; 158(1-2):7-13. PubMed ID: 24269767
[TBL] [Abstract][Full Text] [Related]
17. [Preparation of SOKT1-RTA immunotoxin and its specific cytotoxic effect on human T lymphocytes].
Zhong W; Dai B
Hua Xi Yi Ke Da Xue Xue Bao; 1991 Sep; 22(3):240-4. PubMed ID: 1748404
[TBL] [Abstract][Full Text] [Related]
18. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
[TBL] [Abstract][Full Text] [Related]
19. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
[TBL] [Abstract][Full Text] [Related]
20. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
J Biol Response Mod; 1990 Aug; 9(4):345-54. PubMed ID: 2395000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
